Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 4/20 | 0.33 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.32 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20994607 | 1.00 | GAA (0.33) | GAAMAPTHTTTDP1KDM4E | |
| SCHEMBL29565964 | 0.99 | IDO1 (0.33) | GAAMAPTHTTTDP1KDM4E | |
| SCHEMBL29912733 | 0.99 | IDO1 (0.33) | GAAMAPTHTTTDP1KDM4E | |
| SCHEMBL1133892 | 0.99 | IDO1 (0.33) | GAAMAPTHTTTDP1KDM4E | |
| Hydrochloric Acid SCHEMBL29920895 | 0.87 | KDM4E (0.31) | GAAMAPTHTTTDP1KDM4E | |
| Hydrochloric Acid SCHEMBL6806923 | 0.87 | KDM4E (0.31) | GAAMAPTHTTTDP1KDM4E | |
| SCHEMBL31086299 | 0.86 | SNCA (0.31) | SNCA | |
| SCHEMBL1769919 | 0.82 | MEN1 (0.36) | MAPTTDP1KDM4EALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL498310 | 0.78 | KDM4E (0.33) | GAAMAPTHTTTDP1KDM4E | |
| Hydrochloric Acid SCHEMBL20994598 | 0.78 | KDM4E (0.33) | GAAMAPTHTTTDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149546-A1 | PHOTOSENSITIZER CONJUGATED GOLD NANOPARTICLES FOR RADIOTHERAPY ENHANCEMENT | BIOVENTURES, LLC | 2023-05-18 | — | — | US | claimed |
| WO-2021211975-A1 | PHOTOSENSITIZER CONJUGATED NANOPARTICLES FOR RADIOTHERAPY ENHANCEMENT | BIOVENTURES, LLC (US) | 2021-10-21 | — | — | WO | claimed |
| US-10646570-B2 | Induced photodynamic therapy using nanoparticle scintillators as transducers | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2020-05-12 | — | — | US | claimed |
| EP-3157337-B1 | INDUCED PHOTODYNAMIC THERAPY USING NANOPARTICLE SCINTILLATORS AS TRANSDUCERS | UNIV GEORGIA (US) | 2019-05-29 | — | — | EP | claimed |
| US-20180094292-A1 | Photoactivatable Antimicrobial Agents And Therapeutic And Diagnostic Methods Of Using Same | THE GENERAL HOSPITAL CORPORATION | 2018-04-05 | — | — | US | claimed |
| US-20170209575-A1 | INDUCED PHOTODYNAMIC THERAPY USING NANOPARTICLE SCINTILLATORS AS TRANSDUCERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-27 | — | — | US | claimed |
| EP-3157337-A2 | INDUCED PHOTODYNAMIC THERAPY USING NANOPARTICLE SCINTILLATORS AS TRANSDUCERS | University of Georgia Research Foundation Inc. (US) | 2017-04-26 | — | — | EP | claimed |
| US-20160073634-A1 | BETA-LACTAMASE TARGETED PHOTOSENSITIZER FOR PESTICIDE AND PEST DETECTION | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2016-03-17 | — | — | US | claimed |
| WO-2015195889-A2 | INDUCED PHOTODYNAMIC THERAPY USING NANOPARTICLE SCINTILLATORS AS TRANSDUCERS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2015-12-23 | — | — | WO | claimed |
| EP-2285381-B1 | PHOTOACTIVATABLE BETA-LACTAMASE SUBSTRATES AND ANALYTICAL METHODS OF USING SAME | GEN HOSPITAL CORP (US) | 2015-12-16 | — | — | EP | claimed |
| WO-2006034219-A2 | INACTIVATION OF MICROORGANISMS WITH MULTIDRUG RESISTANCE INHIBITORS AND PHENOTHIAZINIUMS | THE GENERAL HOSPITAL CORPORATION (US) | 2006-03-30 | — | — | WO | claimed |
| US-20040102383-A1 | Growth inhibition and eradication of solid tumors using neuroendocrine resetting therapy and photodynamic therapy | CINCOTTA ANTHONY H (US) | 2004-05-27 | — | — | US | claimed |
| EP-0910365-B1 | GROWTH INHIBITION AND ERADICATION OF SOLID TUMORS USING A PROLACTIN MODULATOR AND A PHOTOSENSITIZER | GEN HOSPITAL CORP (US) | 2003-06-25 | — | — | EP | claimed |
| US-20010049350-A1 | GROWTH INHIBITION AND ERADICATION OF SOLID TUMORS USING NEUROENDOCRINE RESETTING THERAPY AND PHOTODYNAMIC THERAPY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2001-12-06 | — | — | US | claimed |
| EP-0910365-A4 | GROWTH INHIBITION AND ERADICATION OF SOLID TUMORS USING NEUROENDOCRINE RESETTING THERAPY AND PHOTODYNAMIC THERAPY | ERGO RESEARCH CORP (US) | 1999-12-01 | — | — | EP | claimed |
| US-5952329-A | Benzophenothiazine and benzoporphyrin dye combination photodynamic therapy of tumors | THE GENERAL HOSPITAL CORPORATION (US) | 1999-09-14 | — | — | US | claimed |
| EP-0910365-A1 | GROWTH INHIBITION AND ERADICATION OF SOLID TUMORS USING NEUROENDOCRINE RESETTING THERAPY AND PHOTODYNAMIC THERAPY | Ergo Research Corporation (US) | 1999-04-28 | — | — | EP | claimed |
| WO-1997040829-A9 | GROWTH INHIBITION AND ERADICATION OF SOLID TUMORS USING NEUROENDOCRINE RESETTING THERAPY AND PHOTODYNAMIC THERAPY | — | 1998-01-22 | — | — | WO | claimed |
| WO-1997040829-A1 | GROWTH INHIBITION AND ERADICATION OF SOLID TUMORS USING NEUROENDOCRINE RESETTING THERAPY AND PHOTODYNAMIC THERAPY | ERGO RESEARCH CORPORATION (US) | 1997-11-06 | — | — | WO | claimed |
| WO-1997026885-A1 | BENZOPHENOTHIAZINE AND BENZOPORPHYRIN DYE COMBINATION PHOTODYNAMIC THERAPY OF TUMORS | THE GENERAL HOSPITAL CORPORATION DOING BUSINESS AS MASSACHUSETTS GENERAL HOSPITAL (US) | 1997-07-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160073634-A1 | BETA-LACTAMASE TARGETED PHOTOSENSITIZER FOR PESTICIDE AND PEST DETECTION | DDT, BCHE, GUSB | GAA 21/4885EGFR 4419/4885MAPT 2213/4885 |
| US-20180094292-A1 | Photoactivatable Antimicrobial Agents And Therapeutic And Diagnostic Methods Of Using Same | HMBS, GUSB, LCT | GAA 4/4885EGFR 3420/4885MAPT 2958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.